# Allergan

Two products with nothing in common except a habit of publishing the inconvenient part — the largest, least ambiguous cosmetic result in this register alongside two harms that do not reverse, and the only acne label anywhere here that reports the drug working differently in women than in men.

- **Canonical:** https://www.30plusskin.care/brands/allergan
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## The operation

- **Category:** MANUFACTURED PRESCRIPTION DERMATOLOGY · FDA APPROVED
- **Model:** New Drug Application, manufactured product, retail pharmacy dispensing on a prescriber's script.
- **Products assessed:** 2
- **Mean score:** 76/100
- **Mean disclosure score:** 90/100
- **Pricing:** See each offer and billing period in the product records
- **Brand site:** https://www.allergan.com
- **TRADING NAME:** ALLERGAN, INC.
- **MODEL:** NDA → MANUFACTURE → RETAIL PHARMACY
- **RANGE ASSESSED:** 2 PRODUCTS
- **REGULATORY STATUS:** BOTH FDA APPROVED
- **INDICATIONS:** EYELASH HYPOTRICHOSIS · ACNE VULGARIS
- **PACKS:** 3 ML / 70 APPLICATORS · 5 ML / 140 APPLICATORS
- **GENERIC:** AVAILABLE — FROM ~A THIRD OF THE BRAND PRICE

## Verdict

Two products assessed, and they have almost nothing to do with each other clinically. What they share is a willingness to print the thing that complicates the sale: Latisse's postmarketing section names the periorbital fat atrophy that hollows an eyelid, and Aczone's clinical studies section reports that female subjects responded better than male ones — a sex difference in effect, published on a label, which nothing else in this register does.

Latisse is bimatoprost 0.03%, the approved original that the generic and compounded lash serums elsewhere in this register are copies of, and its efficacy is not in question: 78% of subjects improved by at least one Global Eyelash Assessment grade at sixteen weeks against 18% on vehicle, with lash length up 1.4 mm against 0.1 mm.

The disclosure is close to exemplary. Eight separate warning sections. Results published at six timepoints rather than only at the endpoint. Digital image analysis of length, thickness and darkness reported separately from the investigator scale. Both fill volumes published with their applicator counts, so the supply claim can be checked against the manufacturer's own component count — which is the only place in this register that is true.

What makes it conditional is an asymmetry rather than a doubt. The label states that lashes return to pre-treatment level on stopping, that increased brown iris pigmentation is likely to be permanent, and — in postmarketing — that periorbital fat atrophy can deepen the eyelid sulcus and cause ptosis. The benefit is temporary and two of the harms are not. That is a legitimate trade for someone who has read it and a poor one for someone who has not.

The commercial context is the reason this review matters beyond the drug. Brand Latisse averages around $214 for 5 ml; generic bimatoprost starts near $61. The telehealth service at R-32 sells that generic at $175 a bottle and mentions neither the iris nor the eyelid. Everything a buyer needs is on this label, and almost none of it travels with the molecule.

## Patterns in the reviewed range

### 01 — The supply arithmetic actually works

3 ml with 70 applicators, 5 ml with 140, one applicator per eye per night. That is 70 nights from the 5 ml bottle, stated by the manufacturer in the same paragraph as the fill volume. No other product in this register lets a buyer verify a supply claim from the manufacturer's own component count.

### 02 — Permanent harms, reversible benefit

Iris pigmentation is likely to be permanent. Periorbital fat atrophy, deepened eyelid sulcus and ptosis are in postmarketing. Eyelash growth returns to pre-treatment level on discontinuation. A buyer should understand which of those three stops when they do.

### 03 — The worst side effect is filed where nobody reads

Prostaglandin-associated periorbitopathy — hollowing above the eye — sits in section 6.2 rather than in the warnings. For a product bought largely by people trying to look less tired, it is the single most decision-relevant fact on the label, and it is in the section written for pharmacovigilance rather than for patients.

### 04 — The only acne label here that reports a sex difference

Aczone's clinical studies section states that female subjects tended to have greater lesion reductions and greater success than males. Every other label in this register publishes who was enrolled; this one publishes that the drug behaved differently in half of them. It is qualitative and carries no numbers, and it is still the most directly applicable sentence on any acne label we have read.

### 05 — Population-specific risks are named, not gestured at

Aczone's methemoglobinaemia warning states that G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern and Mediterranean ancestry. Latisse warns that iris pigmentation is likely to be permanent and describes how it spreads. In both cases the risk is attached to the people it falls on rather than left abstract.

### 06 — It says the things that reduce sales

Additional applications will not increase growth. Do not apply to the lower lash line. Lashes return to baseline on stopping. Madarosis and eyelash breakage are in postmarketing — lash loss from a lash drug. All four are on the label and none is in any marketing this register has read.

## Credit where it is due

- The largest, least ambiguous efficacy result in this register: 78% against 18%.
- Results published at weeks 1, 4, 8, 12, 16 and 20.
- Digital image analysis of length, thickness and darkness reported separately.
- Both fill volumes published with applicator counts, so cost per night is exact.
- States explicitly that more product will not grow more lashes.
- States explicitly that the effect reverses on discontinuation.
- Instructs single use of each sterile applicator and explains the bacterial keratitis risk.
- Names periorbital fat atrophy, deepened sulcus, ptosis, madarosis and trichorrhexis.
- Warns that iris pigmentation is likely to be permanent and describes how it spreads.
- Declares benzalkonium chloride and its effect on soft contact lenses.
- Flags the interaction with prostaglandin analogues used for intraocular pressure.

## Disclosure matrix

| Product | CONC. ON PAGE | CONC. FINDABLE | CONTRA-INDICATIONS | SIZE | SIDE EFFECTS |
| --- | --- | --- | --- | --- | --- |
| Allergan Latisse | yes | yes | yes | yes | yes |
| Allergan Aczone | yes | yes | yes | yes | yes |

## Reviews

| No. | Product | Stance | Score | Price | Document |
| --- | --- | --- | --- | --- | --- |
| R-46 | Latisse — Bimatoprost ophthalmic solution 0.03% | CONDITIONAL | 81/100 | $214 | /reviews/latisse-bimatoprost-review |
| R-55 | Aczone — Dapsone gel 5% | CONDITIONAL | 71/100 | $56 | /reviews/aczone-dapsone-gel-review |

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._